MedTrace Logo

A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

NCT04829383 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-04-13

No results posted yet for this study

Summary

This will be a nonrandomized, single arm feasibility study with the primary goal of evaluating the safety profile of the combination of atezolizumab and bevacizumab in patients with advanced/metastatic HCC with Child-Pugh B7 and B8 liver disease who have received no prior systemic therapy.

Conditions

Interventions

DRUG

Atezolizumab

1,200 mg

DRUG

Bevacizumab

15 mg/kg

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Rutgers Cancer Institute of New Jersey

    collaborator OTHER

  • Howard S Hochster

    lead OTHER

Principal Investigators

  • Howard S Hochster, DO, MPH · Rutgers Cancer Institute of New Jersey

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-22
Primary Completion
2025-10-31
Completion
2025-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04829383 on ClinicalTrials.gov